GBM cells express inhibitory signals that prevent the immune system from mounting a significant antitumor response, and ongoing clinical trials will assess whether PD-1 and/or CTLA-4 inhibitors can overcome this. This evidence concerns the gene PDCD1 and glioblastoma.